144 related articles for article (PubMed ID: 2787315)
21. 131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma.
Sakahara H; Endo K; Saga T; Hosono M; Kobayashi H; Konishi J
Ann Nucl Med; 1994 May; 8(2):133-7. PubMed ID: 7521194
[TBL] [Abstract][Full Text] [Related]
22. Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma.
Mangner TJ; Tobes MC; Wieland DW; Sisson JC; Shapiro B
J Nucl Med; 1986 Jan; 27(1):37-44. PubMed ID: 3941363
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
[TBL] [Abstract][Full Text] [Related]
24. [Therapeutic possibilities in metastatic pheochromocytoma].
Vierhapper H; Raber W
Zentralbl Chir; 1997; 122(6):494-7. PubMed ID: 9334119
[TBL] [Abstract][Full Text] [Related]
25. Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives.
Beierwaltes WH
Med Pediatr Oncol; 1987; 15(4):188-91. PubMed ID: 3657705
[TBL] [Abstract][Full Text] [Related]
26. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
Coleman RE; Stubbs JB; Barrett JA; de la Guardia M; Lafrance N; Babich JW
Cancer Biother Radiopharm; 2009 Aug; 24(4):469-75. PubMed ID: 19694582
[TBL] [Abstract][Full Text] [Related]
27. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
28. [Nuclear medicine diagnosis and therapy of distant metastases of pheochromocytoma].
Grünwald F; Ruhlmann J; Kozak B; Overlack A; Christ F; Hotze A; Biersack HJ
Dtsch Med Wochenschr; 1988 Feb; 113(8):297-9. PubMed ID: 3277832
[TBL] [Abstract][Full Text] [Related]
29. Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit.
Tristam M; Alaamer AS; Fleming JS; Lewington VJ; Zivanovic MA
J Nucl Med; 1996 Jun; 37(6):1058-63. PubMed ID: 8683301
[TBL] [Abstract][Full Text] [Related]
30. A case of malignant pheochromocytoma treated by 131I-metaiodobenzylguanidine.
Theilade K; Bak M; Olsen K; Nielsen SL; Christensen NJ
Acta Oncol; 1988; 27(3):296-7. PubMed ID: 3415861
[No Abstract] [Full Text] [Related]
31. 131I-MIBG therapy of neural crest tumours (review).
Troncone L; Rufini V
Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
[TBL] [Abstract][Full Text] [Related]
32. [131I-meta-iodobenzylguanidine (MIBG) for the detection and therapy of pheochromocytoma and neuroblastoma].
Nakajo M; Shinohara S
Rinsho Hoshasen; 1987 Apr; 32(4):461-70. PubMed ID: 3613180
[No Abstract] [Full Text] [Related]
33. Discrepant salivary gland response after radioiodine and MIBG therapies.
Jentzen W; Richter M; Poeppel TD; Schmitz J; Brandau W; Bockisch A; Binse I
Q J Nucl Med Mol Imaging; 2017 Sep; 61(3):331-339. PubMed ID: 25566809
[TBL] [Abstract][Full Text] [Related]
34. [Radionuclide therapy of Sipple syndrome using iodine-131 metaiodobenzylguanidine].
Furusawa M; Shimomura O; Tomiguchi S; Hirota Y; Takahashi M; Yamauchi J; Iwaoka D; Satoh T
Kaku Igaku; 1992 Sep; 29(9):1133-8. PubMed ID: 1360550
[TBL] [Abstract][Full Text] [Related]
35. Horizons in radionuclide therapy: 1985 update.
Beierwaltes WH
J Nucl Med; 1985 Apr; 26(4):421-7. PubMed ID: 3884750
[TBL] [Abstract][Full Text] [Related]
36. Preliminary results of [131]metaiodobenzylguanidine treatment in metastatic malignant pheochromocytoma.
Colombo L; Lomuscio G; Vignati A; Dottorini ME
J Nucl Biol Med (1991); 1991; 35(4):300-4. PubMed ID: 1823841
[TBL] [Abstract][Full Text] [Related]
37. Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance.
Wafelman AR; Nortier YL; Rosing H; Maessen HJ; Taal BG; Hoefnagel CA; Maes RA; Beijnen JH
Nucl Med Commun; 1995 Sep; 16(9):767-72. PubMed ID: 7478409
[TBL] [Abstract][Full Text] [Related]
38. [Detection of neural crest tumors by 123I-MIBG scintigraphy].
Ikekubo K; Hino M; Ootsuka H; Ito H; Yamaguchi H; Dan Y; Masui Y; Bito S; Ohta K; Saiki Y
Kaku Igaku; 1994 Nov; 31(11):1357-64. PubMed ID: 7837704
[TBL] [Abstract][Full Text] [Related]
39. Improved detection of disseminated pheochromocytoma using post therapy I-131 MIBG scanning.
Campbell L; Mouratidis B; Sullivan P
Clin Nucl Med; 1996 Dec; 21(12):960-3. PubMed ID: 8957612
[TBL] [Abstract][Full Text] [Related]
40. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
Troncone L; Rufini V
Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
